Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus

Antimicrobial Resistance and Infection Control

Volumn 1, Issue , 2012, Pages

  Storm, Jeremy C ^a,b,d   Diekema, Daniel J ^a,b,d   Kroeger, Jennifer S ^b,c   Johnson, Sarah J ^a,c   Johannsson, Birgir ^a,b,d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d W189Z General Hospital   (United States)

Author keywords

Daptomycin; DNSE; Enterococcus; Non Susceptible; Resistance

Indexed keywords

AMPICILLIN; DAPTOMYCIN; LINEZOLID; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CASE STUDY; CLINICAL ARTICLE; DAPTOMYCIN NONSUSCEPTIBLE ENTEROCOCCUS; DISEASE ASSOCIATION; DRUG EXPOSURE; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; FEMALE; GENETIC HETEROGENEITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; SPECIES IDENTIFICATION; TREATMENT DURATION;

EID: 84872044874     PISSN: None     EISSN: 20472994     Source Type: Journal    
DOI: 10.1186/2047-2994-1-19     Document Type: Article

References (21)

1. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis 2001, 33(2):210-219. 10.1086/321815, 11418881.
2. Centers for Disease Control and Prevention Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002, 51(26):565-567. Centers for Disease Control and Prevention.
3. Linden PK. Optimizing therapy for Vancomycin Resistant Enterococci (VRE). Sem Resp Crit Care Med 2007, 28(6):632-645.
4. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin Infect Dis 2011, 52(2):228-234. 10.1093/cid/ciq113, 21288849.
5. Lesho EP, Wortmann GW, Craft D, Moran KA. De Novo daptomycin nonsusceptibility in a clinical isolate. J Clin Microbiol 2006, 44(2):673. 10.1128/JCM.44.2.673.2006, 1392681, 16455945.
6. Fraher MH, Corcoran GD, Creagh S, Feeney E. Daptomycin non-susceptible enterococci faecium in a patient with no prior exposure to daptomycin. J Hosp Infect 2007, 65(4):376-378. 10.1016/j.jhin.2007.01.002, 17316896.
7. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect Control Hosp Epidemiol 2011, 32(4):391-394. 10.1086/659152, 21460492.
8. Kelesidis T, Humphries R, Uslan DZ, Pegues D. De-novo daptomycin nonsusceptible Enterococcal infections. Emerg Infect Dis 2012, 18(4):674-676. 10.3201/eid1804.110932, 3309676, 22469288.
9. Kelesidis T, Chow ALP, Humphries R, Uslan DZ, Pegues D. Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections. Antimicrob Agents Chemother 2012, 56(4):2150-2152. 10.1128/AAC.05918-11, 22252808.
10. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility testing - Twentieth Information Supplement 2010, CLSI, Wayne, PA, CLSI document M100-S20, Clinical and Laboratory Standards Institute (CLSI).
11. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33(9):2233-2239. 228385, 7494007.
12. Centers for Disease Control and Prevention National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004, 32:470-485. 10.1016/j.ajic.2004.10.001, 15573054, Centers for Disease Control and Prevention.
13. Wisplinghoff H, Bischoff T, Tallent SM, Seiferd H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. 10.1086/421946, 15306996.
14. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med 2002, 162:2223-2238. 10.1001/archinte.162.19.2223, 12390066.
15. Arthur M, Reynolds PE, Depardieu F, Evers S, Dutka-Malen S, Quintiliani R, Courvalin P. Mechanisms of glycopeptide resistance in enterococci. J Infect 1996, 32:11-16. 10.1016/S0163-4453(96)80003-X, 8852545.
16. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, Yeaman MR, Bayer AS. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother 2009, 53(6):2312-2318. 10.1128/AAC.01682-08, 2687258, 19332678.
17. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, Sahl HG, Schrenzel J, Xiong YQ, Bayer AS. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 2008, 52:269-278. 10.1128/AAC.00719-07, 2223911, 17954690.
18. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. Genetic basis for daptomycin resistance in enterococci. Antimicrob Agents Chemother 2011, 55(7):3345-3356. 10.1128/AAC.00207-11, 3122436, 21502617.
19. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, Miller C, Diaz L, Tran TT, Rincon S, Barbu EM, Reyes J, Roh JH, Lobos E, Sodergren E, Pasqualini R, Arap W, Quinn JP, Shamoo Y, Murray BE, Weinstock GM. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011, 365(10):892-900. 10.1056/NEJMoa1011138, 3205971, 21899450.
20. Sader HS, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 2009, 65:158-162. 10.1016/j.diagmicrobio.2009.06.016, 19748426.
21. Sader HS, Moet GJ, Farrell DJ, Jones RN. Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis 2011, 70:412-416. 10.1016/j.diagmicrobio.2011.02.008, 21546202.